Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects

• Status: Completed
• Trial end date: 2016-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a clinical study of a drug named dopamine and how it affects our bodies ability to make and secrete insulin. Insulin is a hormone made in the pancreas that helps our body regulate sugar levels. We think that this drug decreases the amount of insulin our body makes and causes our sugar levels to be high. When you are critically ill there can be many adverse effects if you have sugar levels that are too high.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Albert Einstein College of Medicine; Albert Einstein College of Medicine of Yeshiva University
• Treatments: Dopamine; Dopamine Agents; Insulin

Criteria

Inclusion Criteria:

1. Healthy subjects

2. Age 18-35 years

3. Hemoglobin >12 g/dl

4. Euthyroid or on a stable dose of synthroid

5. Normal EKG, hemoglobin AIC, kidney and liver function

Exclusion Criteria:

1. Prior history of dopamine infusion

2. Past medical history of diabetes, hypertension, myocardial infarction, vaso-occlusive disease or arrhythmias

3. Chronic steroid therapy, oral contraceptive pills, monoamine oxidase inhibitors (MAO-I), anticonvulsants (phenytoin)

4. Pregnant women because dopamine is pregnancy category C

5. Clinical signs of polycystic ovarian syndrome

6. Past medical history of Cushing's disease or pheochromocytoma

7. Sulfa drug allergy

8. Use of any medications or illness determined by the investigators that may affect insulin secretion or insulin sensitivity.